Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

Multiple dysregulated signaling pathways are implicated in the pathogenesis of cancer. The
conventional therapies used in cancer prevention/treatment suffer from low efficacy …

The preclinical drug screening of pancreatic cancer treatments suffers from the absence of
appropriate models capable to reproduce in vitro the heterogeneous tumor …

Background: Pancreatic cancer is highly lethal and aggressive with increasing trend of
mortality in both genders. An effective prediction model is needed to assess prognosis of …

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most challenging lethal
tumors and has a very poor prognosis. In addition to cancer cells, the tumor …

Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …

Chemotherapy remains the mainstay of treatment in the majority of solid and haematological
malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and …

Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …

Background Previous studies have revealed the role of dysregulated urokinase
plasminogen activator (encoded by PLAU) expression and activity in several pathways …

Pancreatic cancer (PC) remains one of the most lethal malignancies across the world, which
is due to delayed diagnosis and resistance to current therapies. The interactions between …